Conference Coverage

VIDEO: Office-based hereditary cancer risk testing is doable


 

REPORTING FROM ACOG 2018


Patients and providers also were surveyed regarding their experience with the new process. Patients overwhelming noted that they understood the information provided (98.8%), and that they were satisfied with the overall process (97.6%). All 15 providers said that they would continue to use the new process in their practice and most – 13 of 15 – said they found the process thorough and felt comfortable recommending genetic counseling without referral to a genetic counselor (2 were undecided).

“I think that this study really proves the concept that in a community-based practice, we can test our patients,” Dr. DeFrancesco said in an interview.

Myriad Genetics sponsored the study. Dr. DeFrancesco reported no financial conflicts of interest. His coauthors include employees of Myriad Genetics, some with ownership interests.

SOURCE: DeFrancesco, MS et al. ACOG 2018 3K.

Pages

Recommended Reading

Gaps exist in receipt of clinically indicated genetic counseling after breast cancer diagnosis
MDedge ObGyn
Possible increased breast cancer risk found in women with schizophrenia
MDedge ObGyn
Fulvestrant plus neratinib reversed treatment-acquired HER2 mutations in metastatic ER+ breast cancer
MDedge ObGyn
Over one-third report financial burden from breast cancer treatment
MDedge ObGyn
Think about breast cancer surveillance for transgender patients
MDedge ObGyn
Sarcopenia, body fat linked with mortality in nonmetastatic breast cancer
MDedge ObGyn
Can cN0 and pCR limit axillary surgery in some breast cancer patients?
MDedge ObGyn
Hormone therapy raises diabetes risk in breast cancer survivors
MDedge ObGyn
Early breast cancer: Patients report favorable quality of life after partial breast irradiation
MDedge ObGyn
How does oral contraceptive use affect one’s risk of ovarian, endometrial, breast, and colorectal cancers?
MDedge ObGyn